Alopecia areata (AA) is an autoimmune disease characterized by hair loss due to the breakdown of immune privilege in hair follicles, initiated by an infammatory response [1], [2]. Baricitinib, an oral Janus kinase (JAK) inhibitor, received approval from the National Medical Products Administration (NMPA) of China in 2023 for treating severe AA based on results from Phase 3 trials (BRAVE-AA1 and BRAVE-AA2) [3], [4]. However, data on its use in Chinese populations remains limited. This retrospective study assesses the efcacy and safety of baricitinib in Chinese patients treated at the Dermatology Department of the First Afliated Hospital of Kunming Medical University between March 2023 and March 2024.
基金：
Program for Innovative Research Team in the Ministry of Education of China (IRT17-R49), Yunnan Revitalization Talent Support Program and Yunnan Province Clinical Center for Skin Immune
Diseases(ZX2019-03–02), First-Class Discipline Team of Skin &
Mucosal Regenerative Medicine of Kunming Medical University
(2024XKTDTS10).
第一作者机构：[1]Kunming Med Univ, Affiliated Hosp 1, 295 Xichang Rd, Kunming, Peoples R China[2]Chenggong Hosp, Kunming Yanan Hosp, 2 Fukang Rd, Kunming, Peoples R China
通讯作者：
推荐引用方式(GB/T 7714)：
Li Wen-fei,Tu Ying,Yang Zheng-hui,et al.Efficacy of baricitinib in treating severe alopecia areata: a retrospective study[J].ARCHIVES OF DERMATOLOGICAL RESEARCH.2024,317(1):doi:10.1007/s00403-024-03498-9.
APA：
Li, Wen-fei,Tu, Ying,Yang, Zheng-hui,Hua, Pi-yan,Yao, Qiu-yan&Gu, Hua.(2024).Efficacy of baricitinib in treating severe alopecia areata: a retrospective study.ARCHIVES OF DERMATOLOGICAL RESEARCH,317,(1)
MLA：
Li, Wen-fei,et al."Efficacy of baricitinib in treating severe alopecia areata: a retrospective study".ARCHIVES OF DERMATOLOGICAL RESEARCH 317..1(2024)
